Thermostabilize Coronavirus Vaccines: Formulation and Process Development and Rapid Scale-up Through Modeling and QbD Experimentation

The aim is to develop vaccine lyophilization formulations and processes to thermostabilize coronavirus vaccine surrogates that pharmaceutical companies could then apply to produce vaccine stockpiles enabling a more rapid response to future outbreaks

Industry Need

The COVID-19 pandemic demonstrated that the reliance on real-time manufacturing and requirements for cold chain storage for current vaccines severely limits the national response to health emergencies.
Two of the current FDA-authorized COVID-19 vaccines (Pfizer & Moderna) and one vaccine in Phase III clinical trials (CureVac) are formulated as Liquid NanoParticle (LNP)-encapsulated mRNA.
Lyophilization, or freeze-drying, of these vaccines would create vaccine stockpiles and reduce logistics burdens during vaccine administration.
These formulations present unique challenges for freeze-drying because each formulation may require different freeze-drying conditions to ensure the vaccine's efficacy is not lost during the freeze-drying process.

Solution

Physical Sciences Inc., NIPTE, and UMass will test LNPs and formulations to determine best practices for freeze-drying future coronavirus vaccines.

The goals of this project are to:

Identify and test candidate vaccine formulations
Develop freeze-drying cycle recipes
Create improvements to process development and scale-up models.

Impacts

Develop vaccine lyophilization formulations and processes to thermostabilize coronavirus vaccine surrogates that pharmaceutical companies could leverage to produce vaccine stockpiles, enabling a more rapid response to future viral outbreaks.